Sawabu N, Toya D, Yoneshima M, Kidani H, Hattori N
Gan No Rinsho. 1984 May;30(6 Suppl):563-8.
The authors discussed the clinical significance and some properties of the novel gamma-GTP isoenzyme (novel gamma-GTP) which was reported to be specific for sera of hepatocellular carcinoma (HCC) in our previous publications. One or more of specific bands (novel gamma-GTP) such as bands II, II' and I' were electrophoretically detectable in 109 (55%) of 200 patients with HCC, but only in 3% of 279 patients with other hepatobiliary diseases. Novel gamma-GTP was found in 38% of HCC patients with AFP levels below 400 ng/ml. The incidence of novel gamma-GTP was independent of the clinical stage as classified by liver scanning. Even in stage I, where filling defects were not seen, the incidence was 52%. It is concluded that novel gamma-GTP is useful in diagnosis of HCC patients with low levels of AFP or at a relatively early stage. Some properties of gamma-GTP purified from HCC tissues were investigated and compared with those of the normal kidney enzyme. The enzymes from HCC and kidney were identical in enzymatic and immunological properties, whereas a considerable difference was observed in electrophoresis, Con A affinity, effect of neuraminidase and isoelectric point. Respective bands II, II' and I' could be differentiated in Con A affinity and neuraminidase reaction. These results support the possibility that novel gamma-GTP in sera of HCC patients is largely due to a difference in carbohydrate moiety of gamma-GTPs.
作者们讨论了新型γ-谷氨酰转肽酶（新型γ-GTP）的临床意义和一些特性，在我们之前的出版物中报道该酶对肝细胞癌（HCC）血清具有特异性。在200例HCC患者中，109例（55%）电泳可检测到一条或多条特异性条带（新型γ-GTP），如条带II、II'和I'，而在279例其他肝胆疾病患者中仅3%可检测到。在AFP水平低于400 ng/ml的HCC患者中，38%发现有新型γ-GTP。新型γ-GTP的发生率与肝脏扫描分类的临床分期无关。即使在I期，未见到充盈缺损，发生率也为52%。结论是新型γ-GTP对AFP水平低或处于相对早期的HCC患者的诊断有用。研究了从HCC组织中纯化的γ-GTP的一些特性，并与正常肾酶的特性进行了比较。来自HCC和肾脏的酶在酶学和免疫学特性上相同，而在电泳、伴刀豆球蛋白A亲和力、神经氨酸酶的作用和等电点方面观察到相当大的差异。在伴刀豆球蛋白A亲和力和神经氨酸酶反应中可以区分各自的条带II、II'和I'。这些结果支持了HCC患者血清中新型γ-GTP很大程度上是由于γ-GTP糖部分差异的可能性。
